Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

Barrett's Esophagus Clinical Trial

Official title:

Randomized Placebo-Controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01298999
• Other study ID #: AAAE9648
• Secondary ID: YFBE-001
• Status: Completed
• Phase: Phase 2
• Start date: June 2010
• Est. completion date: December 2017

Study information

• Verified date: November 2021
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.

Description:

The association between gastro-esophageal reflux disease (GERD) and cancer of the esophagus is well-established. Barrett's esophagus (BE) is a condition in which the lining of the part of the esophagus changes to look like small intestine, and this change occurs in the setting of GERD. Patients with BE are at increased risk for developing esophageal cancer. It is recommended that all patients with BE take medicines called proton pump inhibitors (PPIs), which greatly reduce the acid produced by the stomach, in the hopes of reducing the risk of esophageal cancer. However, by reducing the acid level in the stomach, levels of a hormone called gastrin are increased. There is laboratory data to suggest that gastrin may have effects that actually promote the development of cancer, including esophageal cancer. The investigators previously showed that BE patients with very high gastrin levels are more likely to have either advanced precancerous changes (also called high grade dysplasia) or cancer of the esophagus. As such, the obvious question is raised: does gastrin promote the development of cancer in BE? YF476 is a new drug that blocks the effects of gastrin. Trials in healthy subjects have demonstrated that the drug is safe and well-tolerated. The investigators therefore propose to conduct a randomized placebo-controlled trial of YF476 in patients with Barrett's esophagus. The primary hypothesis is that treatment with YF476 will reduce the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >= 18 years, with histologically confirmed diagnosis of Barrett's Esophagus without dysplasia
• Minimum of 1 cm circumferential Barrett's mucosa on endoscopy or at least 2 cm maximal contiguous extent of Barrett's mucosa
• Proton pump inhibitor use at least once daily for at least twelve months prior to enrolment, and stable dose of PPI for the three months before enrolment
• ECOG performance status = 2 and Karnofsky = 60%
• Normal organ and marrow function
• Use of adequate contraception during the study
• Willingness to comply with all treatment and follow up procedures
• Ability to understand and the willingness to sign a written informed consent document
• Up to date with all age appropriate cancer screening tests, as per American Cancer Society guidelines

Exclusion Criteria:

• Histologically confirmed BE with high grade dysplasia, invasive carcinoma of the esophagus, low grade dysplasia
• Prior endoscopic therapy for BE
• History of esophageal or gastric surgery
• History of atrophic gastritis, pernicious anemia, or Zollinger-Ellison syndrome
• Participation in a trial of an investigational medicinal product within the previous 28 days
• Prolonged QTc interval >450 msec
• History of allergic reactions attributed to compounds of similar chemical composition to YF476
• History of baseline findings of: diabetes mellitus requiring insulin therapy; pancreatitis; hepatitis B, hepatitis C or HIV; malabsorption syndrome or inability to swallow or retain oral medicine; major surgery = 28 days prior to enrollment; ECOG performance status = 2; or another cancer within 3 years except for basal carcinoma of the skin or cervical carcinoma in situ; any clinically significant and uncontrolled major morbidity
• Certain medicines and herbal remedies taken during the 7 days before the start of study drug
• Has evidence of cancer at the time of enrolment, or has surveillance tests planned within 21 weeks after enrollment

Related Conditions & MeSH terms

• Barrett Esophagus
• Barrett's Esophagus

Intervention

Drug:
• YF476
25 mg: one capsule to be taken by mouth once daily for 12 weeks.
• Placebo
Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.

Locations

Country	Name	City	State
United Kingdom	National Institute for Health Research	Cambridge
United States	New York Presbyterian Hospital - Columbia	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Columbia University	Trio Medicines Ltd.

Countries where clinical trial is conducted

United States,  United Kingdom, 

References & Publications (1)

Abrams JA, Del Portillo A, Hills C, Compres G, Friedman RA, Cheng B, Poneros J, Lightdale CJ, De La Rue R, di Pietro M, Fitzgerald RC, Sepulveda A, Wang TC. Randomized Controlled Trial of the Gastrin/CCK(2) Receptor Antagonist Netazepide in Patients with — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Ki67 Expression	The study is designed to examine change in tissue Ki67 expression, a marker of cellular proliferation.	Up to 3 months from baseline
Primary	Number of Participants That Experienced Change in Any Biomarker Expression	Participants with changes in gene expression were assessed by RNA-sequencing (i.e., sample has sufficient RNA for analysis) between baseline and up to 3 months are tallied.	Up to 3 months from baseline
Secondary	Number of Participants That Experienced Adverse Events	A measure of safety and tolerability. Participants with recorded adverse events were tallied. The events include any adverse events and/or severe adverse events.	Up to 4 months from baseline